MILLENNIUM PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1993-01-01
- Employees
- 1K
- Market Cap
- -
A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2013-09-23
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT00652158
- Locations
- 🇪🇸
Ciutat Sanitaria Vall d'Hebron, Barcelona, Spain
A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma
- Conditions
- Follicular Lymphoma
- Interventions
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2012-01-13
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT00636792
- Locations
- 🇺🇸
MidDakota Clinic - Cancer Treatment and Research Center, Bismarck, North Dakota, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma
- First Posted Date
- 2008-03-10
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 205
- Registration Number
- NCT00631631
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT00619489
- Locations
- 🇨🇦
London Health Sciences Centre, London, Ontario, Canada
Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2008-02-08
- Last Posted Date
- 2009-07-14
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT00610792
- Locations
- 🇨🇭
Kantonsspital St. Gallen, St. Gallen, CH, Switzerland
🇨🇭Gynecologic Oncology Unit, Ospedale Sant' Anna, Turin, Switzerland
🇮🇹Istituto Nazionale dei Tumori, Milan, Italy
An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)
- Conditions
- Multiple MyelomaNon-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2012-01-30
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT00608907
- Locations
- 🇮🇱
Hematology Institute - Davidoff Center - Rabin Medical Center, Petach Tikva, Israel
🇵🇱Medical Academy - Dept of Hematology and Transplantology, Gdansk, Poland
🇬🇧Hematology Department Combined Laboratories - Derriford Hospital, Plymouth, United Kingdom
Safety Study of TAK-700 in Subjects With Prostate Cancer.
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2016-04-04
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 123
- Registration Number
- NCT00569153
- Locations
- 🇺🇸
USC Westside Prostate Cancer Center, Beverly Hills, California, United States
🇺🇸Northwestern University Medical Center, Chicago, Illinois, United States
🇺🇸Evanston Hospital, Evanston, Illinois, United States
A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer
- Conditions
- Cancer
- Interventions
- Drug: TAK-285 Dose Escalation CohortsDrug: TAK-285 Recommended Phase 2 Dosing Cohort
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2011-12-09
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT00535522
- Locations
- 🇺🇸
University of Maryland Greenbaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: bortezomib, dexamethasone, and thalidomide
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2012-01-26
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT00531453
- Locations
- 🇦🇹
Wilhelminenspital-1, Vienna, Austria
Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2007-07-26
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 502
- Registration Number
- NCT00507416
- Locations
- 🇺🇸
Hematology Oncology Consultants Inc., Columbus, Ohio, United States
🇺🇸S. Florida Oncology/ Hematology, West Palm Beach, Florida, United States
🇺🇸Hematology-Oncology Clinic, Baton Rouge, Louisiana, United States